Shares of ResMed Inc. RMD inched 0.56% higher to $233.88 Thursday, on what proved to be an all-around mixed trading session ...

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) went into the Christmas break with a small gain. The benchmark index rose 0.25 ...

In total, that means that $60,000 invested across these three ASX 200 shares would now be worth approximately $478,000.

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $237.27, but opened at $230.21. ResMed shares last traded at $226 ...

Shares of ResMed Inc. RMD inched 0.61% higher to $232.58 Tuesday, on what proved to be an all-around positive trading session ...

Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...

Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

I have to say, this list is representative of an industry that has been through a lot.

Even a medical device maker attributed their revenue growth this year in part to the rise of GLP-1 drugs. ResMed (RMD+0.34%), ...